Martin Shkreli, the infamous ex-pharmaceutical executive known for hiking the price of a life-saving drug, pled not guilty Monday to yet another criminal charge. The charge stems from an alleged Ponzi-like scheme in which he swindled his former pharmaceutical company, Retrophin, out of millions to cover losses of two failing hedge funds he managed.

Specifically, federal prosecutors allege with the new charge that Shkreli and his former counsel, Evan Greebel, conspired to conceal Shkreli’s ownership of some Retrophin shares from the Securities and Exchange Commission. The charge is Shkreli’s eighth and Greebel’s second in connection with the alleged scheme. Both men were first indicted in December and have pleaded not guilty to all of the charges.

In a statement, Shkreli’s current lawyer, Benjamin Brafman, said: “There is nothing in the new indictment that impacts in any way on the flawed theory of the case as applied to Mr. Shkreli.”

Still, Brafman, along with Greebel’s attorney, requested that US District Judge Kiyo Matsumoto delay setting a trial date until after they had received all of the documents related to the new charges. Matsumoto agreed, ordering the defendants back to court July 14 to set a trial date, possibly for sometime in early 2017.

In his usual manner, Shkreli appeared smug and confident before, during, and after today’s proceedings, including winking to the press on his way into the Brooklyn courtroom. On his way out, Shkreli smirked and used the popular social media app, Periscope, to live broadcast his return home, including a stop at Dunkin’ Donuts. There, another customer at the restaurant recognized Shkreli and asked how the hearing went, to which Shkreli replied: “It went great, the judge bitch-slapped the government, again.”

The charges Shkreli faces carry a maximum sentence of 20 years. In earlier hearings, Brafman hinted that Shkreli would use a “reliance of counsel” defense, essentially attempting to pin any wrongdoing on Greebel.